Modified vaccinia virus ankara (MVA) – Development as recombinant vaccine and prospects for use in veterinary medicine;Modifiziertes Vacciniavirus Ankara (MVA) – Die entwicklung als vektorimpfstoff und einsatzmöglichkeiten in der veterinärmedizin

Berliner und Munchener Tierarztliche Wochenschrift

Volumn 128, Issue 11-12, 2015, Pages 464-472

  Volz, Asisa ^a   Fux, Robert ^a   Langenmayer, Martin C ^a   Sutter, Gerd ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Infectious diseases; Viral vector vaccines; Zoonoses

Indexed keywords

LIVE VACCINE; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL; DOMESTIC ANIMAL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; IMMUNOLOGY; PROCEDURES; STANDARDS; VACCINIA VIRUS; VETERINARY MEDICINE;

ANIMALS; ANIMALS, DOMESTIC; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VETERINARY MEDICINE; VIRAL VACCINES;

EID: 84948766556     PISSN: 00059366     EISSN: None     Source Type: Journal    
DOI: 10.2376/0005-9366-128-464     Document Type: Article

References (71)

1. Alberca B, Bachanek-Bankowska K, Cabana M, Calvo-Pinilla E, Viaplana E, Frost L, Gubbins S, Urniza A, Mertens P, Castillo-Olivares J (2014): Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge. Vaccine 32: 3670–3674
2. Antoine G, Scheiflinger F, Dorner F, Falkner FG (1998): The complete genomic sequence of the Modified Vaccinia Ankara strain: Comparison with other orthopoxviruses. Virology 244: 365–396
3. Antonis AFG, Van Der Most RG, Suezer Y, Stockhofe-Zurwieden N, Daus F, Sutter G, Schrijver RS (2007): Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 25: 4818–4827
4. Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HGG, Lunn DP (2006): Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 24: 1180–1190
5. Breathnach CC, Rudersdorf R, Lunn DP (2004): Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol 98: 127–136
6. Broder C, Earl P (1999): Recombinant vaccinia viruses. Mol Biotechnol 13: 223–245
7. Broyles SS (2003): Vaccinia virus transcription. J Gen Virol 84: 2293–2303
8. Büttner M, Czerny CP, Lehner KH, Wertz K (1995): Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Vet Immunol Immunopathol 46: 237–250
9. Carson C, Antoniou M, Ruiz-Argüello MB, Alcami A, Christodoulou V, Messaritakis I, Blackwell JM, Courtenay O (2009): A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 27: 1080–1086
10. Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek- Bankowska K, Chiam R, Maan S, Nieto JM, Ortego J, Mertens PPC (2011): A Modified Vaccinia Ankara virus (MVA) vaccine expressing African Horse Sickness Virus (AHSV) VP2 protects against AHSV challenge in an IFNAR −/− mouse model. PLoS ONE 6: e16503
11. Chandran D, Reddy KB, Vijayan SP, Sugumar P, Rani GS, Kumar PS, Rajendra L, Srinivasan VA (2010): MVA recombinants expressing the fusion and hemagglutinin genes of PPRV protects goats against virulent challenge. Ind J Microbiol 50: 266–274
12. Chiam R, Sharp E, Maan S, Rao S, Mertens P, Blacklaws B, Davis-Poynter N, Wood J, Castillo-Olivares J (2009): Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA). PLoS ONE 4: e5997
13. Delaloye J, Roger T, Steiner-Tardivel Q-G, Le Roy D, Knaup Reymond M, Akira S, Petrilli V, Gomez CE, Perdiguero B, Tschopp J, Pantaleo G, Esteban M, Calandra T (2009): Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome. PLoS Pathog 5: e1000480
14. De Vries RD, De Gruyter HLM, Bestebroer TM, Pronk M, Fouchier RAM, Osterhaus ADME, Sutter G, Kreijtz JHCM, Rimmelzwaan GF (2015): Induction of influenza (H5N8) antibodies by Modified Vaccinia virus Ankara H5N1 vaccine. Emerg Infect Dis 21:1086-1088
15. Drexler I, Staib C, Kastenmüller W, Stevanović S, Schmidt B, Lemonnier FA, Rammensee H-G, Busch DH, Bernhard H, Erfle V, Sutter G (2003): Identification of vaccinia virus epitopespecific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA 100: 217–222
16. European Medicines Agency (2013): Imvanex: modifiziertes Vacciniavirus Ankara lebend. EMA/490157/2013 European Medicines Agency, London,United Kingdom.
17. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (1988): Smallpox and its Eradication. World Health Organization, 6th ed. Geneva.
18. Förster R, Wolf G, Mayr A (1994): Highly attenuated poxviruses induce functional priming of neutrophils in vitro. Arch Virol 136: 219–226
19. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y (2013): Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. N Eng J Med 368: 1888–1897
20. Gilbert SC (2013): Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 31: 4241–4246
21. Gómez CE, Perdiguero B, García-Arriaza J, Esteban M (2013): Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines 12: 1395–1416
22. Graham RL, Donaldson EF, Baric RS (2013): A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Micro 11: 836–848
23. Halle S, Dujardin HC, Bakocevic N, Fleige H, Danzer H, Willenzon S, Suezer Y, Hämmerling G, Garbi N, Sutter G, Worbs T, Förster R (2009): Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med 206: 2593–2601
24. Haller SL, Peng C, McFadden G, Rothenburg S (2014): Poxviruses and the evolution of host range and virulence. Infect Gen Evolut 21: 15–40
25. Herrlich A, Mayr A (1957): Pockenimpfstoff aus Zungengewebekulturen vom Rind. Arch ges Virusforsch 7: 284–296
26. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M, Elkins WR, Alvord WG, Montefiori DC, Moss B, Lifson JD (1996): Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70: 3741–3752
27. Imai M, Herfst S, Sorrell EM, Schrauwen EJA, Linster M, De Graaf M, Fouchier Ra M, Kawaoka Y (2013): Transmission of influenza A/H5N1 viruses in mammals. Virus Res 178: 10.1016/j.virusres.2013.1007.1017
28. Kreijtz JHCM, Gilbert SC, Sutter G (2013): Poxvirus vectors. Vaccine 31: 4217–4219
29. Kreijtz JHCM, Goeijenbier M, Moesker FM, Van Den Dries L, Goeijenbier S, De Gruyter HLM, Lehmann MH, Mutsert GD, Van De Vijver Da M C, Volz A, Fouchier RaM, Van Gorp ECM, Rimmelzwaan GF, Sutter G, Osterhaus ADME (2014): Safety and immunogenicity of a modified-vacciniavirus- Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. The Lancet Infect Dis 14: 1196–1207
30. Kreijtz JHCM, Suezer Y, De Mutsert G, Van Amerongen G, Schwantes A, Van Den Brand JMA, Fouchier RaM, Löwer J, Osterhaus ADME, Sutter G, Rimmelzwaan GF (2009a): MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS ONE 4: e7790
31. Kreijtz JHCM, Suezer Y, de Mutsert G, van Den Brand JMA, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RaM, Löwer J, Osterhaus ADME, Sutter G, Rimmelzwaan GF (2009b): Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 27: 6296–6299
32. Kreijtz JHCM, Suezer Y, Van Amerongen G, de Mutsert G, Schnierle BS, Wood JM, Kuiken T, Fouchier RaM, Löwer RaM, Osterhaus ADME, Sutter G, Rimmelzwaan GF (2007): Recombinant Modified Vaccinia virus Ankara–based vaccine induces protective immunity in mice against infection with influenza virus H5N1 J InfectDis 195: 1598–1606
33. Kreijtz JHCM, Wiersma LCM, De Gruyter HLM, Vogelzang- Van Trierum SE, Van Amerongen G, Stittelaar KJ, Fouchier RaM, Osterhaus ADME, Sutter G, Rimmelzwaan GF (2015): A single immunization with Modified Vaccinia virus Ankara– based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. J Infect Dis 211: 791–800
34. Kremer M, Suezer Y, Volz A, Frenz T, Majzoub M, Hanschmann K-M, Lehmann MH, Kalinke U, Sutter G (2012a): Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog 8: e1002557
35. Kremer M, Volz A, Kreijtz JHCM, Fux R, Lehmann MH, Sutter G (2012b): Easy and efficient protocols for working with recombinant vaccinia virus MVA. Meth Mol Biol 890: 59–93
36. Lane JM, Millar JD (1969): Routine childhood vaccination against smallpox reconsidered. N Engl J Med 281: 1220–1224
37. Lehmann MH, Kastenmüller W, Kandemir J, Brandt F, Suezer Y, Sutter G (2009): Modified Vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol 83: 2540–2552
38. Mackett M, Smith GL, Moss B (1982): Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79: 7415–7419
39. Mayr A, Munz E (1964): Veränderung von Vaccinevirus durch Dauerpassagen in Hühnerembryofibroblastenkulturen. Zentralbl Bakteriol Parasit Infek Hyg 1 Orig 195: 24–35
40. Mayr A, Hochstein-Mintzel V, Stickl H (1975): Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia- Stammes MVA. Infection 3: 6–14
41. Mayr A, Stickl H, Müller H (1978): The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl Bakteriol B 167: 375–390
42. McFadden G (2005): Poxvirus tropism. Nat Rev Micro 3: 201–213
43. Meyer H, Sutter G, Mayr A (1991): Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J GenVirol 72: 1031–1038
44. Milne Price S, Miazgowicz KL, Munster VJ (2014): The emergence of the Middle East Respiratory Syndrome coronavirus, Vol 71, 121–136 pp.
45. Moss B (1996): Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci 93: 11341–11348
46. Nam J-H, Wyatt LS, Chae S-L, Cho H-W, Park Y-K, Moss B (1999): Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine 17: 261–268
47. Nam Jh CS, Hw Cho (2002): Immunogenicity of a recombinant MVA and a DNA vaccine for Japanese encephalitis virus in swine. Microbiol Immunol 46: 23–28
48. Panicali D, Paoletti E (1982): Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 79: 4927–4931
49. Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuß T, Hanschmann K-M, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G (2009): Postexposure immunization with Modified Vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis 199: 39–48
50. Price P, Torres-Dominguez L, Brandmuller C, Sutter G, Lehmann MH (2013): Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine 31: 4231–4234
51. Price P, Bánki Z, Scheideler A, Stoiber H, Verschoor A, Sutter G, Lehmann MH (2015): Complement component C5 recruits neutrophils in the absence of C3 during respiratory infection with Modified Vaccinia virus Ankara. J Immunol 194: 1164–1168
52. Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V (2008): Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26: 333–344
53. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS (1987): Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease. N Eng J Med 316: 673–676
54. Rosales R, López-Contreras M, Rosales C, Magallanes-Molina J-R, Gonzalez-Vergara R, Arroyo-Cazarez JM, Ricardez-Arenas A, Del Follo-Valencia A, Padilla-Arriaga S, Guerrero MV, Pirez MA, Arellano-Fiore C, Villarreal F (2014): Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gen Ther 25: 1035–1049
55. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, Chaplin P, Suter M, O’keeffe M, Hochrein H (2008): Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 118: 1776–1784
56. Sivan G, Ormanoglu P, Buehler EC, Martin SE, Moss B (2015): Identification of restriction factors by human genome-wide RNA interference screening of viral host range mutants exemplified by discovery of SAMD9 and WDR6 as inhibitors of the vaccinia virus K1L-C7L-mutant. mBio 6: e01122-15
57. Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, Osterhaus ADME, Haagmans BL, Sutter G (2013): Middle East Respiratory Syndrome coronavirus spike protein delivered by Modified Vaccinia virus Ankara efficiently induces virusneutralizing antibodies. J Virol 87: 11950–11954
58. Stickl H, Hochstein-Mintzel V, Mayr A (1974): MVA-Stufenimpfung gegen Pocken. Dtsch med Wochenschr 99: 2386–2392
59. Su S, Bi Y, Wong G, Gray GC, Gao GF, Li S (2015): The epidemiology, evolution and recent outbreaks of avian influenza viruses in China: A Review. J Virol 89: 8671–8676
60. Sutter G (1990): Das Genom des Vacciniavirusstammes Ankara und seine Änderung während der Attenuierung. München, LMU Tierärztliche Fakultät, Diss.
61. Sutter G, Moss B (1992): Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89: 10847–10851
62. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B (1994): A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12: 1032–1040
63. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet J-C, Cox WI, Davis SW, an Der Hoeven J, Meignier B, Riviere M, Languet B, Paoletti E (1992): NYVAC: a highly attenuated strain of vaccinia virus. Virology 188: 217-232
64. Valdez Graham V, Sutter G, José MV, García-Carranca A, Erfle V, Moreno Mendoza N, Merchant H, Rosales R (2000): Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer 88: 1650–1662
65. Van Den Doel P, Volz A, Roose JM, Sewbalaksing VD, Pijlman GP, Van Middelkoop I, Duiverman V, Van De Wetering E, Sutter G, Osterhaus ADME, Martina BEE (2014): Recombinant Modified Vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. PLoS Negl Trop Dis 8: e3101
66. Veits J, Römer-Oberdörfer A, Helferich D, Durban M, Suezer Y, Sutter G, Mettenleiter TC (2008): Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 26: 1688–1696
67. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, Sutter G (2015): Protective efficacy of recombinant Modified Vaccinia virus Ankara (MVA) delivering Middle East Respiratory Syndrome coronavirus spike glycoprotein. J Virol 89: 8651–8656
68. Volz A, Langenmayer M, Jany S, Kalinke U, Sutter G (2014): Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with Modified Vaccinia virus Ankara. J Virol 88: 10946–10957
69. Waibler Z, Anzaghe M, Frenz T, Schwantes A, Pöhlmann C, Ludwig H, Palomo-Otero M, Alcamí A, Sutter G, Kalinke U (2009): Vaccinia virus-mediated inhibition of type I interferon responses Is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol 83: 1563–1571
70. Wyatt LS, Earl PL, Eller LA, Moss B (2004): Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 101: 4590–4595
71. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RaM (2012): Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367: 1814–1820.